Objective In patients suffering multiple sclerosis activity despite treatment with interferon β
or glatiramer acetate, clinicians often switch therapy to either natalizumab or fingolimod. …

Importance Within 2 decades of onset, 80% of untreated patients with relapsing-remitting
multiple sclerosis (MS) convert to a phase of irreversible disability accrual termed secondary …

The complexity of multiple sclerosis (MS) treatment means that doctors and decision-makers
need the best available evidence to make the best decisions for patient care. Randomized …

Objective To identify predictors of 10‐year Expanded Disability Status Scale (EDSS) change
after treatment initiation in patients with relapse‐onset multiple sclerosis. Methods Using …

The aim of this work was to evaluate sex differences in the incidence of multiple sclerosis
relapses; assess the relationship between sex and primary progressive disease course; and …

A number of studies have been conducted with the onset of secondary progressive multiple
sclerosis as an inclusion criterion or an outcome of interest. However, a standardized …

Background and Objectives People with multiple sclerosis (MS) are a vulnerable group for
severe coronavirus disease 2019 (COVID-19), particularly those taking immunosuppressive …

Background High-efficacy therapies in multiple sclerosis are traditionally used after
unsuccessful treatment with first-line disease modifying therapies. We hypothesised that early …

Prevention of irreversible disability is currently the most important goal of disease modifying
therapy for multiple sclerosis. The disability outcomes used in most clinical trials rely on …

Relapses (episodic exacerbations of neurological signs or symptoms) are a defining feature
of relapsing-remitting multiple sclerosis (MS), the most prevalent MS phenotype. While their …